Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02817633 | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | PHASE1 | ACTIVE NOT_RECRUITING | 463 | — | — | Jul 8, 2016 | Mar 1, 2027 | Oct 28, 2025 | 89 | United States, South Korea +1 |
| Arm | Type | Description |
|---|---|---|
| Part 1a: TSR-022 monotherapy | EXPERIMENTAL | - |
| Part 1b: TSR-022 in combination with nivolumab | EXPERIMENTAL | - |
| Part 1c: TSR-022 in combination with TSR-042 | EXPERIMENTAL | - |
| Part 1d: TSR-022 in combination with TSR-042 and TSR-033 | EXPERIMENTAL | - |
| Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1) | EXPERIMENTAL | - |
| Part 1f: TSR-022 in combination with TSR-042 and Docetaxel | EXPERIMENTAL | - |
| Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin | EXPERIMENTAL | - |
| Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin | EXPERIMENTAL | - |
| Part 2: Cohort A Melanoma-TSR-022 as monotherapy | EXPERIMENTAL | - |
| Part 2: Cohort A Melanoma-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy | EXPERIMENTAL | - |
| Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy | EXPERIMENTAL | - |
| Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel | EXPERIMENTAL | - |
| Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TSR-022 | DRUG | TSR-022 will be administered. |
| Nivolumab | DRUG | Nivolumab will be administered. |
| TSR-042 | DRUG | TSR-042 will be administered. |
| TSR-033 | DRUG | TSR-033 will be administered. |
| Docetaxel | DRUG | Docetaxel will be administered. |
| Pemetrexed | DRUG | Pemetrexed will be administered. |
| Cisplatin | DRUG | Cisplatin will be administered. |
| Carboplatin | DRUG | Carboplatin will be administered. |
Inclusion Criteria * Participant is at least 18 years of age. * Female participants of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential. * Participant has an ECOG per...